NYSE:KVUE
Kenvue (KVUE)
Financials 
Technical Analysis 
Aug 14, 2026, 12:00 amThis summary was created by AI, based on 2 opinions in the last 12 months.
Kenvue (KVUE-N) is viewed as a stable and consistent player in the market, often described as 'dull and boring' but a solid addition to an investment portfolio. Analysts highlight the strength of Kenvue's essential brands, many of which are staples in everyday life, which adds to their appeal. The anticipated acquisition by KMB is seen as a positive move, likely to enhance the company's value and expand its market multiple, moving it from the low teens. Additionally, while there are concerns regarding the Tylenol controversy, analysts are optimistic about the company's resilience against generic brands and potential risks associated with AI. With an attractive yield of 4.78% and a price target of $19.23, Kenvue is positioned for stable growth in the upcoming year.
Quality, essential brands we love and use daily. Attracted by spinoffs, as they tend to attract interest. Tylenol controversy from Trump pushed price down. Generic brands don't affect many of their products. Attractive multiple compared to PG and CL.
Likes the deal with KMB, which should close sometime next year. Multiple should expand. Not impacted by AI as far as he can tell ;) Yield is 4.78%.
Martin Cobb, ASIP
Consumer staples are outperforming in the last few days, and that speaks to the advantage of having a balanced portfolio. Companies like KHC, UL, KVUE, and Nestle. It's not that they won't be affected (their costs would go up), but they're far less cyclical than other businesses. Earnings will be much more stable. Earnings could fall 10%, but not 50%. Dividends will be sustained.
Companies like Unilever and Nestle are huge in NA, but huge globally as well.
An activist investor is inside the company now. Pays a 3.5% dividend. Not followed that much by Wall Street, but offers decent growth.
Lorne SteinbergConsumer health spinoff from J&J. First rate consumer products business. Trading at discount to peers in sector. ~4% dividend attractive. Excellent array of brands in portfolio. Litigation always a concern, but overall not worried for the long term.
Lorne Steinberg
- «
- ‹
- 1
- ›
- »
Popular Articles
Kenvue (KVUE) Frequently Asked Questions
What is Kenvue stock symbol?
Kenvue is a American stock, trading under the symbol KVUE (previously KVUE-N on Stockchase) on the New York Stock Exchange (KVUE). It is usually referred to as NYSE:KVUE or KVUE
Is Kenvue a buy or a sell?
In the last year, 2 stock analysts issued a Buy, Sell, or Hold rating on KVUE (previously KVUE-N on Stockchase). 2 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is BUY. Read the latest stock experts' ratings for Kenvue.
Is Kenvue a good investment or a top pick?
Kenvue was recommended as a Top Pick by Martin Cobb, ASIP on 2026-07-16. Read the latest stock experts ratings for Kenvue.
Why is Kenvue stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Kenvue.
Is Kenvue worth watching?
Kenvue is followed by 15 investors on Stockchase and is a trending stock that is worth watching.
What is Kenvue stock price?
On 2026-08-13, Kenvue (KVUE) stock closed at a price of $19.20.
Being acquired by KMB. Multiple's in low teens. Classic steady Eddie. Dull and boring, but good to have in your portfolio.